HIV-1 gp41 fusion intermediate: a target for HIV therapeutics (Q37703732)

22 August 2017

1 reference

title

HIV-1 gp41 fusion intermediate: a target for HIV therapeutics (English)

1 reference

22 August 2017

0 references

3

Shibo Jiang

1 reference

22 August 2017

Chungen Pan

1

1 reference

PubMed ID

20206833

22 August 2017

Shuwen Liu

series ordinal

2

1 reference

22 August 2017

1 February 2010

1 reference

Journal of the Formosan Medical Association

22 August 2017

1 reference

22 August 2017

109

1 reference

22 August 2017

94-105

1 reference

22 August 2017

2

1 reference

HIV-1 at Age 25: Some Thoughts for Taiwan and China

22 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Antiviral drugs in current clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

The prevalence of antiretroviral drug resistance in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Adverse effects of antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Peptide and non-peptide HIV fusion inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

A trimeric structural domain of the HIV-1 transmembrane glycoprotein.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Core structure of gp41 from the HIV envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Atomic structure of the ectodomain from HIV-1 gp41

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

HIV entry and its inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

HIV-1 inhibition by a peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Atomic structure of a thermostable subdomain of HIV-1 gp41

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

C-terminal octylation rescues an inactive T20 mutant: implications for the mechanism of HIV/SIMIAN immunodeficiency virus-induced membrane fusion

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Novel therapies based on mechanisms of HIV-1 cell entry.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naive and -experienced patients

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Evolution of genotypic and phenotypic resistance during chronic treatment with the fusion inhibitor T-1249.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Short constrained peptides that inhibit HIV-1 entry

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Crystal structure of GCN4-pIQI, a trimeric coiled coil with buried polar residues

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Potent D-peptide inhibitors of HIV-1 entry

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Rational design of highly potent HIV-1 fusion inhibitory proteins: implication for developing antiviral therapeutics.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Recombinant protein of heptad-repeat HR212, a stable fusion inhibitor with potent anti-HIV action in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Protein design of an HIV-1 entry inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Conserved salt bridge between the N- and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Design, synthesis, and structure-activity relationship of a novel series of 2-aryl 5-(4-oxo-3-phenethyl-2-thioxothiazolidinylidenemethyl)furans as HIV-1 entry inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusion

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Evaluation of "credit card" libraries for inhibition of HIV-1 gp41 fusogenic core formation

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

A fluorescence assay for rapid detection of ligand binding affinity to HIV-1 gp41

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

A novel fluorescence intensity screening assay identifies new low-molecular-weight inhibitors of the gp41 coiled-coil domain of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Selection of T1249-resistant human immunodeficiency virus type 1 variants

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Resistance to enfuvirtide, the first HIV fusion inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

The LLSGIV stretch of the N-terminal region of HIV-1 gp41 is critical for binding to a model peptide, T20

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960029-0

7 January 2021

10.1016/S0929-6646(10)60029-0

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20206833